BerGenBio AS (BerGenBio)

Oncology Corporate Profile

HQ Location

Jonas Lies vei 91
Bergen, Norway 5009

Company Description

BerGenBio AS is a clinical stage biopharmaceutical company. The company is committed to developing innovative therapeutics that inhibit EMT, prevent the formation of cancer stem cells and disrupt the cellular mechanisms that drive acquired cancer drug resistance. The company is founded on proprietary platform technology, CellSelectâ„¢, which uses information from RNAi screening studies to identify and validate novel drug targets and biomarkers. BGB324 is the first compound in BerGenBio's pipeline to enter clinical trials in AML and NSCLC, with additional compounds and drug targets at different stages of preclinical development.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BGB324axl kinase inhibitorChronic Myelogenous Leukemia (CML)II
BGB324axl kinase inhibitorAcute Myelogenous Leukemia (AML)I
BGB324axl kinase inhibitorNon Small Cell Lung Cancer (NSCLC)I
BGB324 (+ doxetaxol)axl kinase inhibitorNon Small Cell Lung Cancer (NSCLC)I
BGB324 (+ erlotinib)axl kinase inhibitorNon Small Cell Lung Cancer (NSCLC)I

View additional information on product candidates here »


Recent News Headlines

There are no news items to display